| INTRODUCTION

Chronic hepatitis C virus (HCV) infection is estimated to globally
affect 70-100 million people. 1 Genotype 4 infects 10-15 million persons; a large percentage of whom are living in Egypt, where HCV-G4 represents more than 90% of the infected population. 2 During the last few years, management of HCV became more effective with the appearance of different classes of direct antiviral agents (DAA). They raised the sustained virological responses (SVR)
rates from around 40% with pegylated interferon (PEG) and ribavirin (RBV) 3 to more than 90%. 4, 5 Different combinations afforded the possibility of interferon-free regimens with unprecedented success rates. 6 Daclatasvir (DCV) is a potent HCV NS5A replication complex inhibitor which is active against HCV-G4, 7, 8 sofosbuvir (SOF) is a pan-genotypic NS5B polymerase inhibitor that showed a good safety profile as well as a high barrier to resistance. 9 The combination of both drugs led to appreciable success rates, [10] [11] [12] [13] including patients in different special populations as HIV-coinfected patients, advanced liver diseases, pre-and post-transplant settings and haemodialysis patients. 8, [14] [15] [16] [17] [18] [19] [20] [21] In Egypt, the National Committee for the Control of Viral Hepatitis (NCCVH) started a mass treatment program 22 that was initially based on SOF in combination with RBV for a treatment duration of 24 weeks or in combination with PEG and RBV for 12 weeks, during the period from October 2014 till May 2015, with SVR12 rates of 78.4% and 94% respectively. 23, 24 This was followed by an era of combined SOF and simeprevir (SMV) therapy that provided an overall 94% SVR12. 25 Starting November 2015, generic SOF+DCV (with or without RBV) became the main line of therapy in the national program, due to a cost saving of more than 80% of the reduced cost of the brand medications that were being used in the program.
Real-world experience has the benefit to overcome limitations of clinical studies. It assesses the actual situation of the drugs without exclusion criteria applied by the studies for optimisation. It truly assesses the efficacy and safety on a large scale of patients. Here, we present the real-world experience of using SOF-DCV regimen with or without RBV in the management of HCV genotype 4, which has been scarcely represented in previous clinical trials.
| PATIENT AND METHODS
| Study population
This report presents data prospectively collected from 18 378 viremic HCV patients with chronic liver disease, mostly infected with HCV-G4. They were consecutively recruited from patients who started treatment during the first 2 months of the introduction of the generic forms of SOF and DCV (in November and December 2015), in the viral hepatitis specialised treatment centres affiliated to the NCCVH in Egypt where the generic medications were first introduced.
The national treatment program in Egypt included all patients
≥18 years old with chronic HCV infection, and although initially treatment with DAAs was prioritised to patients with advanced No dose adjustments were attempted for SOF or DCV. Records of co-medications were not analysed for this report.
| Endpoints
The primary efficacy endpoint was the proportion of patients achiev- 
| Safety assessments
Safety endpoints included graded AEs, serious AEs, discontinuations due to AEs, deaths, and laboratory abnormalities. 27 All patients were included in the safety assessment. All assessments were performed at each individual centre based on standard local practice and recommendations of the NCCVH. Laboratory tests for assessments of biochemical and hematological parameters, and safety assessments were recommended at baseline, treatment week 4, EOT (week 12) and post-treatment week 12.
| Covariates
Data about the following variables were obtained from all patients included in the analyses.
| Demographics and clinical data
Age, gender, body mass index (BMI), previous treatment status (na€ ıve or experienced) and if treatment experienced, details about previously administered medications.
| Laboratory, imaging, and endoscopic data
Data were collected at baseline, and included blood count, AST, ALT, 
| Statistical analysis
The primary population for efficacy and safety analyses included patients who received one dose of either treatment regimens. Data were entered, validated, and analysed using STATA | 423 factors associated with SVR12. Data were presented as odds ratios (ORs) with 95% confidence intervals (95% CI). All statistical analyses were based on two-sided hypothesis tests with a significance level of P < .05.
3 | RESULTS
| Patients
Data were available for 18 378 enrolled patients who received treatment with SOF-DCV (n = 10 120) or SOF-DCV-RBV (n = 8258) during the first 2 months of introducing the generic drugs to the national program (November and December 2015). Figure 1 shows the patient's disposition, and the numbers included in each treatment arm. Mean age was 49.4 AE 11.6 years; most patients were females (57.6%) and treatment na€ ıve (93.0%). Baseline data revealed frequent comorbidities, including obesity, diabetes and hypertension (Table 1) .
Assignment of treatment was nonrandomised, but was based on previous treatment history, and indicators of the presence of advanced fibrosis or cirrhosis. "Easy-to-treat" patients were treated without RBV, and "difficult-to-treat" patients were treated with SOF-DCV-RBV for 12 weeks. Forty-four treatment-na€ ıve patients with normal laboratory tests were treated as "difficult-to-treat" with RBV in addition to SOF-DCV due to incorrect initial evaluation categorising them as having cirrhosis, and their results are among the 8258 patients in the RBV group, and 395 treatment-experienced patients were incorrectly treated as "easy-to-treat" patients without additional RBV. Despite being an exclusion criterion, 35 patients with ascites were included, 14 patients as "easy-to-treat" and 21
patients as "difficult-to-treat".
As a result of assignment criteria, more patients treated with SOF-DCV-RBV had signs suggestive of advanced liver disease, including higher proportions of patients with coarse liver echo-texture on ultrasound (33.0% vs 16.9%, P < .001), ascites (0.3% vs 0.1%, P = .001) and oesophageal varices (2.0% vs 0.6%, P < .001; Table 1 ). Table 2) .
| Efficacy outcomes
Among patients who failed treatment, more patients treated with SOF-DCV-RBV discontinued therapy than those treated with SOF-DCV (2.0% vs 1.0%, P < .001), while primary nonresponse occurred slightly more among those treated without RBV (2.6% vs 2.2%, P = .14). Relapse rates were similar in both cohorts (P = .9; Table 2 ).
Among patients treated with SOF-DCV-RBV (n = 8258), patients with normal laboratory tests (n = 59) who were treatment experienced (n = 15) all responded to treatment, and those who were treatment na€ ıve and allocated to this group by an error at inclusion (n = 44) had an SVR12 rate of 95.6%. Patients receiving RBV because of the presence of cirrhosis or abnormal liver tests who were treatment na€ ıve (n = 7313) had an SVR12 rate of 94.5%, and those with previous treatment history (n = 886) had an SVR12 rate of 96.2%. No significant differences in SVR12 rates were observed between groups of patients who received SOF-DCV-RBV (P = .17; Table 3 ).
Compared to those who did not achieve SVR12 (n = 905), patients who achieved SVR12 were younger (P = .002), more females (P < .001), had lower prevalence of diabetes (P = .02), lower | 425 ALT (P < .001), AST (P < .001), bilirubin (P < .001), and FIB4
(P < .001), and had higher albumin (P < .001), haemoglobin (P = .02), leucocytes (P = .01) and platelets (P < .001; Table 4 ).
Forty-nine per cent (442/905) of patients who did not achieve SVR12 were on-treatment nonresponders, 29.4% discontinued treatment and 21.8% relapsed after the EOT. Baseline clinical and laboratory parameters of patients who failed treatment (nonresponders and those who discontinued or relapsed) are shown in Table 5 .
| Baseline predictors of SVR12
Independent predictors for treatment failure in each treatment group are shown in Table 6 . PEG-RBV or SOF-RBVAEPEG experienced patients included by error as "easy-to-treat" patients (n = 395) responded to treatment similar to those who were treated with additional RBV (Table 6 ).
| Safety and tolerability
Treatment was prematurely discontinued in 1.45% of patients (n = 266), including 5 deaths while on-treatment. All reported deaths were among patients receiving SOF-DCV-RBV and were due to decompensation and liver failure. One hundred SOF+DCV recipients (0.99%) discontinued medications; the most common causes of discontinuation were patient withdrawal (n = 76) or pregnancy (n = 5).
The most frequent reported adverse events were hematological (n = 4), decompensation and/or development of ascites (n = 3). Serious adverse events were reported in six patients receiving SOF-DCV. Treatment discontinuation rate was higher (n = 166, 2.01%) among SOF-DCV-RBV recipients; the most common cause was patient withdrawal (n = 136). The most frequent adverse events were decompensation and/or development of ascites (n = 9) and hematological complications (n = 5). Serious adverse events were reported in only three patients receiving DCV-SOF-RBV. Most of T A B L E 2 Assessment of treatment efficacy among studied patients (n = 18 378) Parameter SOF-DCV (n = 10 120) SOF-DCV-RBV (n = 8258) P (Table 7) .
| DISCUSSION
We report a real-world experience with generic DCV and SOF with or without RBV for treating patient with HCV-G4. This is one of the largest reports presenting real-life data, and of using this combination in treating HCV-G4 patients. Although genotyping was not performed at baseline, more than 90% of patients in Egypt are infected with HCV-G4, and this report can thus be taken to represent results of HCV-G4 treatment.
Optimising treatment outcomes in patients with cirrhosis includes either the addition of RBV or prolonging treatment duration. [28] [29] [30] [31] The NCCVH unified treatment duration to 12 weeks and categorised patients to two groups: the so called "easy-to-treat" patients were patients who were treatment na€ ıve, and had no cirrhosis or had normal liver tests. They were treated with SOF-DCV for 12 weeks without RBV. Patients who had previously failed interferon-or SOF-based therapy, patients with cirrhosis, and those who had serum albumin <3.5 g/dL, bilirubin >1.2 mg/dL, INR>1.2 and/or platelet count <150 000/cmm were considered "difficult-to-treat"
and were treated with SOF-DCV-RBV for 12 weeks. The assignment criteria resulted in differences between both groups, and in addition, the "difficult to treat" group included a higher proportion of patient with obesity, diabetes and hypertension. Despite these assignment criteria, patients were occasionally assigned incorrectly. That experienced patients assigned by error as "easy-to-treat" (n = 395) responded to treatment without RBV similar to those treated as "difficult-to-treat" suggests that patients who previously failed PEG-RBV or SOF-RBVAEPEG are not "difficult-to-treat" using SOF-DCV.
When the NCCVH modified the local guidelines to be based entirely on SOF-DCV or SOF-DCV-RBV combinations, the decision was an economic decision based on the cost of the available local generic medications vs original imported drugs. There were very limited published data on SOF-DCV use in HCV-G4, and efficacy was assumed based on inference from results of SOF-DCV based therapy in HCV-G1 patients. Sulkowski et al recruited HCV-G1, 2 and 3 patients without cirrhosis who were either treatment na€ ıve or experienced. SVR12 ranged between 89%-98% depending on genotype. 8 ALLY-3 and ALLY-3+ studies focused on genotype 3 patients and achieved 86%-92% SVR rates. 17, 27 Pol et al reported a real-world experience for 768 HCV-G1 patients, and found an overall 95% SVR12 rate (92-99%), and that the SVR rates were not affected by treatment duration or RBV use. 12 The only local clinical trial using DCV in HCV-G4 patients was in combination with PEG-RBV, and the SVR24 rate in patients treated with DCV 60 mg/day plus PEG-RBV was 100%. 32 The ALLY-1 trial used SOF+DCV in patients with advanced cirrhosis or post-liver-transplantation and included only 4
HCV-G4 patients, who all responded to treatment. 18 Similarly, the ALLY-2 trial treated patients with HCV-HIV coinfection and included T A B L E 5 Baseline characteristics of the patients who did not achieve SVR (n = 905) In this large real-world report of HCV-G4 patients treated with SOF-DCV, the "easy-to-treat" patients achieved 95.4% SVR12 and the "difficult-to-treat" patients including previous treatment failures, patients with cirrhosis, and/or advanced liver disease based on laboratory tests achieved a 94.7% SVR12 rate. We find that using SOF-DCV, with or without RBV, led to a high SVR12 rate among a large group of HCV-G4 patients, under-represented in previous reports.
Similar high response rates have been reported with the use of SOF plus DCV with or without RBV from real-life cohorts, even in elderly patients with several concomitant medications (though with much fewer patients).
19,33-35
Sulkowski et al found that SVR12 rates did not differ after sub analysis of various factors such as sub-genotypes, IL28 phenotype, race, RBV use and history of previous treatment failure with first generation protease inhibitors. 10 Poordad et al found lower albumin levels associated with nonresponse in Child C patients as a reflection of impaired hepatic function. 36 We found several factors that could impact SVR12
rates. These include gender, bilirubin, albumin, INR and platelets.
In this group of patients, only 266 patients (1.45%) prematurely stopped treatment for safety or other reasons, mostly in the group treated with RBV. Treatment was well tolerated: only 0.3% (n = 54) of our patients reported adverse events, serious adverse events, pregnancy and deaths. All previous studies concluded that SOF-DCV combination is safe with limited AEs. High incidence of serious complications (17.5%) was reported by Coilly et al as they managed HCV recurrence in transplanted patients. 20 Such patients are a peculiar situation due to multiple factors that coexist as multi drug intake, immunosuppression and possible drug-drug interactions.
An important factor in this report is the sole use of generic SOF-DCV in all treated patients. Although DAAs provide high cure rates, their high prices could be a barrier to rapid universal treatment uptake. [37] [38] [39] Although the price of SOF in the United States was initially set at 84 000 USD for 12 weeks of treatment, Gilead Sciences and the Egyptian NCCVH reached a marked reduced price for the access program in Egypt, at almost 1% of original price (900 USD for 12 weeks' supply of SOF). Gilead Sciences also provided a "voluntary" license agreement to certain manufacturers to produce generic SOF. This allowed low and middle-income countries to obtain generics from these manufacturers. Thus, different Indian generic manufacturers were allowed to produce and sell generic SOF, ledipasvir and velpatasvir in more than 100 countries, including Egypt. As the Egyptian programme for the control and eradication of HCV infection escalated, the need arose for much larger drug production at much lower costs. 35 The MoH strongly supported local producers of generic DAAs by providing "fast track registration" of generic DAAs including SOF and DCV provided they reduced their prices. 
